A Phase I, Open-Label, Randomized, 3-Panel, 3-way Crossover Trial in Healthy Adult Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of 2 Liquid Formulations or 2 Different Capsule Concept Formulations Compared ot the Phase III 150 mg Capsule, and to Assess the Effect of Food on the Bioavailability of TMC435 Following Administration of the Liquid Formulations.
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2012
At a glance
- Drugs Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 09 Jul 2012 Actual number of patients changed from 13 to 72, as reported by ClinicalTrials.gov.
- 18 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual patients number is 13 as reported by ClinicalTrials.gov.